Opioid-potentiated Volative Anaesthetic Vs. Remifentanil And Propofol During Abdominal Aortic Aneurysm Surgery (ABSENT)
This study has been completed.
Sponsor:
Sykehuset i Vestfold HF
Collaborator:
Oslo University Hospital
Information provided by (Responsible Party):
Espen Lindholm, Sykehuset i Vestfold HF
ClinicalTrials.gov Identifier:
NCT00538421
First received: October 1, 2007
Last updated: March 8, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Comparing 2 different anaesthetic methods during abdominal aortic aneurysm surgery. The patients will be followed up 30 days postoperative. Number of patients included will be 200. Perioperative details will be analyzed.
| Condition | Intervention | Phase |
|---|---|---|
|
Aortic Diseases Abdominal Aneurysm Surgery |
Drug: Propofol Drug: Sevoflurane |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Opioid-potentiated Volative Anaesthetic(Sevoflurane)Compared to Remifentanil and Propofol During Abdominal Aortic Aneurysm Surgery |
Resource links provided by NLM:
Further study details as provided by Sykehuset i Vestfold HF:
| Enrollment: | 193 |
| Study Start Date: | March 2008 |
| Study Completion Date: | March 2013 |
| Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 |
Drug: Propofol
Infusion intravenously (IV) 0-10 mg/kg/h
|
| Active Comparator: 2 |
Drug: Sevoflurane
0,7-1,5 MAC
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients who are planned for open, elective abdominal aortic aneurysm surgery.
- ASA group 1-4.
Exclusion Criteria:
- Patients below 18 years.
- Patients who are included in other pharmaceutical studies.
- Opioids-, benzodiazepins-, antiepileptic drugs-, alcohol- and α2-agonists abuse.
- Pregnant and breastfeeding women.
- Patients with familiar history of malignant hyperthermia.
- Patients with known hypersensitivity for opioids, propofol or volative anaesthetics.
- Patients with considerable arrythmia (atrial fibrillation /atrial flutter is acceptable). Uncontrolled hypertension, serious psychiatric disease.
- Patients with unstable angina pectoris or myocardial infarction last month before inclusion.
- Acute abdominal aortic surgery. Acute dissection or rupture.
- Planned laparoscopic abdominal aortic aneurysm surgery.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Espen Lindholm, Chief consultant, Sykehuset i Vestfold HF |
| ClinicalTrials.gov Identifier: | NCT00538421 History of Changes |
| Other Study ID Numbers: | S-07294b (REK), 2007-000002-79 (Eudract), 17089 (NSD) |
| Study First Received: | October 1, 2007 |
| Last Updated: | March 8, 2013 |
| Health Authority: | Norway:National Committee for Medical and Health Research Ethics Norway: Norwegian Medicines Agency Norway: Norwegian Social Science Data Services |
Keywords provided by Sykehuset i Vestfold HF:
|
propofol Anaesthesia Sevoflurane |
Abdominal Aortic Aneurysm |
Additional relevant MeSH terms:
|
Aneurysm Aortic Aneurysm Aortic Diseases Aortic Aneurysm, Abdominal Vascular Diseases Cardiovascular Diseases Anesthetics Propofol Sevoflurane Remifentanil Analgesics, Opioid Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anesthetics, Intravenous Anesthetics, General Hypnotics and Sedatives Platelet Aggregation Inhibitors Hematologic Agents Anesthetics, Inhalation Analgesics Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on May 16, 2013